Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.The New England Journal of Medicine|August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D Shanafelt, Xin V Wang, Neil E Kay, et al.Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.Blood|April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trialTait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.American Journal of Hematology|March 13, 2020
Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effectsAnthony D Sung, Shekeab Jauhari, Sharareh Siamakpour-Reihani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic SyndromesAziz Nazha, Rami Komrokji, Manja Meggendorfer, et al.Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.Blood|January 20, 2019
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403Wendy Stock, Selina M Luger, Anjali S Advani, et al.Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.Pageof 4